Compare LKFN & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LKFN | ANAB |
|---|---|---|
| Founded | 1872 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2009 | 2015 |
| Metric | LKFN | ANAB |
|---|---|---|
| Price | $61.44 | $46.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $66.00 | ★ $87.25 |
| AVG Volume (30 Days) | 225.3K | ★ 435.1K |
| Earning Date | 10-26-2026 | 11-17-2026 |
| Dividend Yield | ★ 3.31% | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ 3.31 | N/A |
| Revenue | $985,000.00 | ★ $234,603,000.00 |
| Revenue This Year | $6.70 | N/A |
| Revenue Next Year | $5.38 | $69.42 |
| P/E Ratio | $19.00 | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $54.36 | $30.27 |
| 52 Week High | $64.55 | $73.30 |
| Indicator | LKFN | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 64.63 | 45.07 |
| Support Level | $58.59 | $44.38 |
| Resistance Level | $64.14 | $51.94 |
| Average True Range (ATR) | 1.43 | 2.37 |
| MACD | 0.46 | 0.20 |
| Stochastic Oscillator | 84.77 | 44.54 |
Lakeland Financial Corp is a bank holding company. It provides commercial, retail, wealth advisory, and investment management services. It offers a broad line of products and services throughout its Northern and Central Indiana markets. The company provides commercial and consumer banking services, as well as trust and wealth management, brokerage, and treasury management commercial services. It serves a wide variety of industries including, among others, commercial real estate, manufacturing, agriculture, construction, retail, wholesale, finance and insurance, accommodation and food services, and healthcare. The company's revenue is derived from the business of banking.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).